Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $37.25.

Several research analysts recently issued reports on the company. Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Citigroup lifted their price objective on Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th.

Insider Buying and Selling

In other news, Director William Lis sold 8,506 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the transaction, the director owned 41,931 shares in the company, valued at approximately $1,048,275. The trade was a 16.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ying Du sold 7,026 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $18.53, for a total transaction of $130,191.78. Following the sale, the chief executive officer owned 1,203,784 shares of the company’s stock, valued at approximately $22,306,117.52. This trade represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,411 shares of company stock worth $365,337 in the last 90 days. Corporate insiders own 4.88% of the company’s stock.

Institutional Trading of Zai Lab

A number of large investors have recently bought and sold shares of ZLAB. Nykredit A S bought a new stake in Zai Lab in the second quarter valued at $79,000. Headlands Technologies LLC boosted its position in shares of Zai Lab by 142.0% during the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after purchasing an additional 39,901 shares in the last quarter. Finally, Seven Fleet Capital Management LP grew its stake in shares of Zai Lab by 74.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after buying an additional 58,158 shares during the period. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Price Performance

ZLAB opened at $24.98 on Wednesday. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $34.72. The company’s 50 day moving average price is $23.80 and its two-hundred day moving average price is $20.99. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -14.61 and a beta of 0.83.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. The business had revenue of $106.31 million for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. As a group, equities research analysts predict that Zai Lab will post -2.37 EPS for the current year.

Zai Lab Company Profile

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company’s research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections.